Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
CINME abre sus puertas en el 2007. Su misión es mejorar la calidad de vida de sus pacientes, a través de la atención médica asistencial humana e integral, siendo un centro educador para la comunidad y aportando datos cualitativos al avance científico en el marco de la investigación clínica. Hemos incorporado nuevas áreas terapéuticas en el campo de la salud, buscando ser en cada una un centro modelo para el diagnóstico y tratamiento de enfermedades, y al mismo tiempo de referencia en el campo de la investigación clínica. Teniendo como ideal la excelencia, hemos hecho especial énfasis en los procesos que nos aportan altos estándares de calidad en nuestro trabajo. Por ello, en el 2019 certificamos en calidad en los procesos de investigación clínica a través de IRAM-ISO 9001-2015.Viamonte 2213, C1056ABI Cdad. Autónoma de Buenos Aires, Argentina
Websitehttp://www.cinme.com.ar
Select an option
I am a doctor
I am a sponsor
Specializations
Dermatitis atópica
Diabetes
Hepatitis autoinmune
Colitis ulcerosa
Enfermedad de Crohn
Fibrosis pulmonar
Fibrosis pulmonar idiopática
Cardiovascular
Nefropatía
Our team
Medical staff
Gisela Burattini
Daniela Saravia
Lucia Escalona Barrios
Emilia Pastormerlo
Luisa Ramallo
Solana Alderete Morillo
Camila Rotta
Gabriela Romero
Juan Jose Herrera Paz
Daniela Creuso
Yenisca Nataly Zambrano Novoa
Jacklyn D'Moya
Sebastian Scazzola
Stephanie Dorado
Belen Barbosa
Lucia Maria Chaves
Zaira Agustina Pereyra
Sofia Razzini
Maria Cristina Grossman
Matias Vincenzini
Catalina Hermida
Malena Vassolo
Carolina Romero
Maria Belen Vigna
Antonela Menna
Ana Maria Freuler
Nerina Samanta Rodriguez Giambagli
Gonzalo Saenz
Alejandra Romeo
Angela Romero Zarante
Mónica Rondinón
Liliana González
Mariana Abal
Ricardo Galimberti
Maria Laura Galimberti
Griselda Russo
María Otaola
Maria Otaola
Fernando Halac
Raquel Analia González
Estanislao Jesus Gomez
Maria Julia Garay
Gonzalo Saenz
Alberto Casey
Daniela Camargo
Daniel Seinhart
Federico Carlos Perez Manghi
Maria de Lourdes Figuerola
María Margarita Anders
Estanislao Gómez
Adriana Ellenberg
Mariana Paula Blas
Maria Otaola
Lucas Manghi
Laura Gazzotti
Open studies
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) - SURMOUNT-ADOLESCENTS-2 - Eli Lilly and CompanySee more
Alzheimer disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) - ADEPT-4 - Karuna TherapeuticsSee more
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) - TRAILBLAZER-ALZ 5 - Eli Lilly and CompanySee more
Pulmonary fibrosis
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) - TETON-PPF - United TherapeuticsSee more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata - BRAVE-AA-PEDS - Eli Lilly and CompanySee more
Lung cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer - DESTINY-Lung06 - Daiichi SankyoSee more
Breast Cancer
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) - MK-6482-029 LITESPARK-029 - Merck Sharp & Dohme LLCSee more
Dermatitis
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor - AQUA - SanofiSee more
Renal disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease - NN C0519-0130 - Novo Nordisk A/SSee more
